MVAL - ETF AI Analysis
Top Page
VanEck Morningstar Wide Moat Value ETF (MVAL)
MVAL (VanEck Morningstar Wide Moat Value ETF) has a solid overall rating, suggesting it holds a generally strong mix of quality companies with durable competitive advantages. Key holdings like Broadridge Financial Solutions and GE Healthcare support the fund’s rating through strong financial performance, positive outlooks, and strategic growth initiatives, while names like Clorox and Mondelez, which face bearish trends, leverage or operational challenges, slightly weigh on the score and highlight risks around financial stability and execution. Investors should also note that several holdings show signs of potential overvaluation or bearish technical trends, which can add volatility even within this otherwise quality-focused portfolio.
MVAL vs. SPDR S&P 500 ETF (SPY)
- AUM
- 2.96M
- Region
- North America
- Expense Ratio
- 0.50%
- Beta
- 0.73
- Issuer
- VanEck
- Inception Date
- Mar 26, 2024
- Dividend Yield
- 1.60%
- Asset Class
- Equity
- Index Tracked
- Morningstar US Broad Value Wide Moat Focus Index - Benchmark TR Gross
MVAL Summary
MVAL is the VanEck Morningstar Wide Moat Value ETF, which follows the Morningstar US Broad Value Wide Moat Focus Index. It invests mainly in U.S. companies that Morningstar believes have strong, lasting competitive advantages and are currently undervalued. The fund holds well-known names like Danaher and Mondelez International, spread across defensive sectors such as consumer goods and health care. Someone might invest in MVAL for long-term growth with diversification into high-quality value stocks. A key risk is that these stocks can still go up and down with the overall stock market, and value companies can stay out of favor for long periods.
How much will it cost me?
This ETF has an expense ratio of 0.50%, which means you’ll pay about $5 per year for every $1,000 invested. That’s higher than the average low-cost index ETF because this fund is more specialized and follows an actively designed strategy focusing on “wide moat” value companies.
What would affect this ETF?
MVAL focuses on U.S. companies with strong competitive advantages in defensive areas like consumer staples and health care, which could benefit if the economy slows and investors favor steady, resilient businesses, and it may also gain from renewed interest in value stocks if interest rates stabilize or fall. On the downside, the fund could lag if growth and tech stocks lead the market, if higher interest rates or regulatory changes hurt U.S. consumer and health care companies, or if its value style and concentrated sector exposure fall out of favor.
MVAL Top 10 Holdings
MVAL leans heavily into U.S. consumer defensive and health care names, with a few stocks doing the heavy lifting. Danaher and GE Healthcare are rising and help power the fund, while Kenvue’s steady-to-strong run adds support from the defensive side. On the flip side, Tractor Supply and McCormick are lagging, acting like weights on the portfolio, and Constellation Brands has been mixed, offering more sizzle than follow-through. Overall, the ETF is concentrated in wide-moat, U.S.-based staples and medical names, giving it a resilient but somewhat conservative profile.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 DHR | Danaher | 4.97% | $147.88K | $163.38B | 7.99% | 75Outperform |
 GEHC | GE Healthcare Technologies Inc | 4.68% | $139.47K | $34.62B | 2.09% | 78Outperform |
 BR | Broadridge Financial Solutions | 4.55% | $135.39K | $20.19B | -19.09% | 78Outperform |
 KVUE | Kenvue, Inc. | 4.41% | $131.35K | $37.09B | 35.60% | 73Outperform |
 BF.B | Brown-Forman B | 4.32% | $128.54K | $13.29B | 7.65% | 74Outperform |
 ZBH | Zimmer Biomet Holdings | 4.31% | $128.37K | $18.03B | -5.06% | 73Outperform |
 MDLZ | Mondelez International | 4.17% | $124.06K | $82.20B | 12.40% | 62Neutral |
 TSCO | Tractor Supply | 4.24% | $126.25K | $17.68B | -37.29% | 73Outperform |
 STZ | Constellation Brands | 3.98% | $118.62K | $22.90B | 5.00% | 67Neutral |
 MKC | McCormick & Company | 3.84% | $114.47K | $12.73B | -26.24% | 73Outperform |
MVAL Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MVAL, the sentiment is Positive. The current price of 39.51 is above the 20-day moving average (MA) of 38.20, above the 50-day MA of 38.10, and above the 200-day MA of 37.34, indicating a bullish trend. The MACD of 0.48 indicates Negative momentum. The RSI at 65.41 is Neutral, neither overbought nor oversold. The STOCH value of 66.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MVAL.
MVAL Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| MVAL | $39.51 | $41.00(3.76% Upside) | $2.96M | 0.50% | 69Neutral |
 RAUS | $29.78 | $36.54(22.70% Upside) | $77.50M | 0.03% | 74Outperform |
 SASS | $23.69 | $29.76(25.64% Upside) | $77.53M | 0.75% | 68Neutral |
 CVAR | $32.26 | $34.89(8.14% Upside) | $47.32M | 0.87% | 58Neutral |
 GVLE | $48.30 | $56.65(17.30% Upside) | $40.82M | 0.45% | 70Outperform |
 NXTI | $36.78 | $44.08(19.86% Upside) | $13.74M | 0.25% | 72Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MVAL | VanEck Morningstar Wide Moat Value ETF | 39.51 | 4.99 | 14.45% | |
| RAUS | RACWI US ETF | 29.78 | 3.53 | 13.45% | |
| SASS | M.D. Sass Concentrated Value ETF | 23.69 | -1.43 | -5.68% | |
| CVAR | Cultivar ETF | 32.26 | 4.92 | 17.98% | |
| GVLE | Goldman Sachs Value Opportunities ETF | 48.30 | 9.20 | 23.52% | |
| NXTI | Simplify Next Intangible Core Index ETF | 36.78 | 4.12 | 12.63% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.